RESEARKA

By contrast, the evidence within this outcome class presents notable tensions regarding rapamycin's effects. Harinath 2025 reports a negative or complex effect direction in their human cohort analysis, while Lesniewski 2016 reports mixed positive findings in a murine model of aging. Shavlakadze 2018 shows null findings for certain outcomes in their preclinical rat model, in contrast to the positive vascular effects seen by Lesniewski 2016. The CARE 2015 pilot protocol represents an early-stage human effort without reported outcomes, creating a knowledge gap between the human observational data of Harinath 2025 and the mechanistic animal data of Lesniewski 2016 and Shavlakadze 2018. Britton 2025's isolated positive finding in bone density does not resolve the fundamental disagreement between the mixed preclinical results and the negative signal from the human pharmacokinetic cohort.

Citation Support

• source_1 Moel 2025
• source_2 Gkioni 2025
• source_3 Smiaek 2023
• source_4 Willows 2023
• source_5 Harinath 2025